603127 Stock Overview
Provides preclinical and non-clinical services in the United States, the People’s Republic of China, and internationally. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 2/6 |
Joinn Laboratories(China)Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥17.68 |
52 Week High | CN¥27.20 |
52 Week Low | CN¥12.32 |
Beta | 0.66 |
11 Month Change | 1.84% |
3 Month Change | 34.14% |
1 Year Change | -33.71% |
33 Year Change | -75.67% |
5 Year Change | 16.16% |
Change since IPO | 57.22% |
Recent News & Updates
Recent updates
Shareholder Returns
603127 | CN Life Sciences | CN Market | |
---|---|---|---|
7D | -0.6% | -2.3% | -0.9% |
1Y | -33.7% | -29.5% | 5.4% |
Return vs Industry: 603127 underperformed the CN Life Sciences industry which returned -29.5% over the past year.
Return vs Market: 603127 underperformed the CN Market which returned 5.4% over the past year.
Price Volatility
603127 volatility | |
---|---|
603127 Average Weekly Movement | 8.8% |
Life Sciences Industry Average Movement | 10.3% |
Market Average Movement | 8.3% |
10% most volatile stocks in CN Market | 12.6% |
10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 603127 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603127's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1995 | 2,585 | Dapeng Gao | www.joinn-lab.com |
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People’s Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models.
Joinn Laboratories(China)Co.,Ltd. Fundamentals Summary
603127 fundamental statistics | |
---|---|
Market cap | CN¥12.04b |
Earnings (TTM) | -CN¥912.86k |
Revenue (TTM) | CN¥2.12b |
6.1x
P/S Ratio9,999x
P/E RatioIs 603127 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
603127 income statement (TTM) | |
---|---|
Revenue | CN¥2.12b |
Cost of Revenue | CN¥1.47b |
Gross Profit | CN¥653.83m |
Other Expenses | CN¥654.75m |
Earnings | -CN¥912.86k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0012 |
Gross Margin | 30.78% |
Net Profit Margin | -0.043% |
Debt/Equity Ratio | 0% |
How did 603127 perform over the long term?
See historical performance and comparison